Ryota Shibaki

Wakayama, 6418510, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 41 publications

Docetaxel plus ramucirumab immediately after immunotherapy in advanced NSCLC: A phase II study (DRUN).

Docetaxel plus ramucirumab immediately after immunotherapy in advanced NSCLC: A phase II study (DRUN).

Journal: Lung cancer (Amsterdam, Netherlands)

Published: May 05, 2026

Three versus six weeks of corticosteroids for mild immune-related pneumonitis: a randomized trial.

Three versus six weeks of corticosteroids for mild immune-related pneumonitis: a randomized trial.

Journal: American journal of respiratory and critical care medicine

Published: January 25, 2026

Atezolizumab Combined With Cisplatin Plus Vinorelbine as Adjuvant Therapy for Completely Resected NSCLC With EGFR Mutation (West Japan Oncology Group 11719L: ADJUST Study).

Atezolizumab Combined With Cisplatin Plus Vinorelbine as Adjuvant Therapy for Completely Resected NSCLC With EGFR Mutation (West Japan Oncology Group 11719L: ADJUST Study).

Journal: JTO clinical and research reports

Published: November 13, 2025

Implementing generative artificial intelligence in precision oncology: safety, governance, and significance.

Implementing generative artificial intelligence in precision oncology: safety, governance, and significance.

Journal: Journal of hematology & oncology

Published: November 02, 2025

Addition of Immune Checkpoint Inhibitor to Platinum Retreatment for Recurrent Non-Small Cell Lung Cancer After Perioperative Chemotherapy: A Multicenter Retrospective Study.

Addition of Immune Checkpoint Inhibitor to Platinum Retreatment for Recurrent Non-Small Cell Lung Cancer After Perioperative Chemotherapy: A Multicenter Retrospective Study.

Journal: Thoracic cancer

Published: September 19, 2025

A clinically applicable and generalizable deep learning model for anterior mediastinal tumors in CT images across multiple institutions.

A clinically applicable and generalizable deep learning model for anterior mediastinal tumors in CT images across multiple institutions.

Journal: Scientific reports

Published: May 19, 2025

A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours.

A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours.

Journal: BMJ open

Published: May 02, 2025

Investigation of cardiotoxicity in patients treated with osimertinib: findings from the OSI-FACT study.

Investigation of cardiotoxicity in patients treated with osimertinib: findings from the OSI-FACT study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: January 21, 2025

Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS).

Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS).

Journal: Clinical lung cancer

Published: January 01, 2025

Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learning.

Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learning.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 28, 2024

Comparison of the Immune Checkpoint InhibitorFree Survival Between Patients Who Completed and Those Who Discontinued ICI for Non-Small Cell Lung Cancer.

Comparison of the Immune Checkpoint InhibitorFree Survival Between Patients Who Completed and Those Who Discontinued ICI for Non-Small Cell Lung Cancer.

Journal: Thoracic cancer

Published: November 26, 2024

Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: A multicenter, open-label prospective trial.

Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: A multicenter, open-label prospective trial.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: July 07, 2024

Showing 1-12 of 41

Last Updated: 09/26/2026